- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, January 26, 2024
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from mHealthIntelligence referenced a study published in the January 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Characterizing Telehealth Use in the US: Analysis of the 2022 Health Information National Trends Survey,” concluded that discussing the motivation of patients to use telehealth could help policy makers and administrators to maximize health care access and quality.
An article from Good Men Project referenced an article published in the April 2021 issue of AJMC. The piece, “Enhance Care Continuity Post COVID-19,” argued that the pandemic had created an opportunity to augment continuity to improve patient-centered outcomes and improve spending efficiency.
An article from Biospace referenced an article published on AJMC.com, the website of AJMC. The article, “Analysis Explores Gene Therapy’s Potential to Be Cost-Effective in SCD,” reported gene therapy in the treatment of sickle cell disease could be cost effective if it was priced below the $2 million mark.
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML
August 16th 2025Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
Read More
In Study Across 15 Centers, 35% of Patients With MCL See Progression After CAR T-Cell Therapy
August 15th 2025Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression after CAR T-cell therapy, highlighting treatment challenges and outcomes.
Read More
